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Abstract | The incidence of cancer is continuing to rise and risk-tailored early diagnostic and/or primary prevention strategies are urgently required. The ideal risk-predictive test should: integrate the effects of both genetic and nongenetic factors and aim to capture these effects using an approach that is both biologically stable and technically reproducible; derive a score from easily accessible biological samples that acts as a surrogate for the organ in question; and enable the effectiveness of risk-reducing measures to be monitored. Substantial evidence has accumulated suggesting that the epigenome and, in particular, DNA methylation-based tests meet all of these requirements. However, the development and implementation of DNA methylation-based risk-prediction tests poses considerable challenges. In particular, the cell type specificity of DNA methylation and the extensive cellular heterogeneity of the easily accessible surrogate cells that might contain information relevant to less accessible tissues necessitates the use of novel methods in order to account for these confounding issues. Furthermore, the engagement of the scientific community with health-care professionals, policymakers and the public is required in order to identify and address the organizational, ethical, legal, social and economic challenges associated with the routine use of epigenetic testing.
programmes in both the prevention and early detection of cancer 8 . For prostate cancer, for example, screening programmes specifically targeted to men with a higher risk than that of the general age-matched population could reduce the proportion of men likely to be overdiagnosed with, and consequently overtreated for prostate cancer 9, 10 . Currently, several biomarker tests and complementary statistical models have been developed to predict an individual's cancer risk (TABLE 2) . With notable exceptions, such as a model based on testing for human papilloma virus DNA to predict a precursor of cervical cancer (cervical intraepithelial neoplasia (CIN) grade 2 or 3) 11 , most risk models include only epidemio logical factors. The discriminative ability of these models in separating those with a low risk from those with a high risk of cancer is modest, as expressed by the area under the receiver operating characteristic curve (ROC-AUC). This measure indicates the discriminatory accuracy of a model in terms of the probability that a test correctly discriminates affected or at-risk individuals from unaffected or non-at-risk individuals. AUC values range from 0.5, which indicates a total lack of discrimination, to 1.0, which indicates perfect discrimination. Furthermore, current models do not typically enable differentiation between individuals with a poor prognosis and those with a good prognosis, which is vital for the use of both tailored screening and primary prevention approaches (such as early detection and/or prevention of cancers that would otherwise lead to death).
The ideal predictive test should: integrate measures of genetic factors with those of nongenetic factors that are both biologically stable and technically reproducible and can be captured using an omics-based technology; derive a risk-prediction score, using easily accessible tissues, that is either relevant to cancer development or is able to capture risk-inducing factors; and, ideally, have the added potential of enabling the effectiveness of potential risk-reducing measures to be monitored. The basis of this strategy is drawn from cardio vascular medicine. In this area of medicine, risk prediction and tailored chemoprevention for nonsymptomatic individuals have both been fundamental aspects of the dramatic reduction in mortality from myocardial infarction and stroke achieved between the years 1975 and 2000 (REF. 12 ). The cardiovascular community has long accepted the principles that freedom from symptoms does not necessarily equate to a guarantee of health and that the identification and use of surrogate end points is central to their success. Both blood pressure and cholesterol concentrations in plasma can be easily assessed using noninvasive measures, act as surrogates for an individual's interaction with environmental factors (such as stress, nutrition, smoking, and/or an absence of physical exercise) and are key components of multivariable risk algorithms 13 . Phenotypic variability between different populations is also known to take place both at the genetic and epigenetic levels, indicating that epigenetic modifications make a substantial contribution to natural human variations 14 . Correspondingly, we propose the introduction of a novel population-based screening methodology that relies upon epigenetics as a surrogate marker for cancer risk prediction.
In this Review, we discuss the potential of markers of DNA methylation to predict the risk of developing specific cancers and highlight the importance of epigenome-wide association studies (EWAS). Epigenetic alterations are tissue-specific, and therefore, one of the biggest challenges is to identify easily accessible surrogate cells and develop algorithms enabling the assessment of cellular heterogeneity. In addition, we address the legal, ethical and economic challenges, along with other aspects associated with the implementation of epigenetic tests into routine clinical use and/or with population-based screening and other areas of cancer-related public health.
Epigenetics in cancer development
Epigenetic traits can be mitotically and meiotically (or transgenerationally) inherited, although, unlike genetic traits, they are not conferred by the sequence of bases that define the genetic code. Epigenetics, rather, is defined by a collective of dynamic processes that fine tune
Key points
• Epigenetic misprogramming is an essential component of cancer development.
• DNA methylation-based risk-prediction models provide novel opportunities for risk-tailored screening and prevention of cancer.
• Multidisciplinary collaborative research is needed to overcome the scientific challenges associated with the discovery of DNA methylation markers for risk-prediction, such as identifying surrogate tissues and developing novel analytical methods.
• Implementation of epigenome-based risk-tailored screening and prevention programmes requires several ethical, legal, social, organizational and economic challenges to be addressed in addition to the engagement of policymakers, health-care professionals and the public. and regulate gene expression. As such, epigenetics can be considered the 'editor' of the genome, affording our cells their identity and providing a certain level of genomic plasticity, particularly at key timepoints such as during early development 15 , in the maintenance and function of tissues during adulthood and in response to lifetime environmental exposures. Three interacting components -DNA methylation, histone modification and non-coding RNA -are integral to epigenetic regulation and, by extension, tissue-specific function. Methylation of cytosines at the C5 position within CpG dinucleotides is technically and biologically the most stable component of the epigenome and can be modified both by inherent genetic components and by all non heritable factors that shape the development and/or function of living organisms 16 . Nevertheless, CpGs reflect, at best, ~2% of the spatial genome and are predominantly concentrated within short stretches of DNA located within gene promoter regions, which are known as CpG islands. In cancer tissues, hypermethylation of CpG islands against a background of global hypomethylation, both of which are associated with skewed gene-expression patterns, are hallmarks of epigenetic modulation that are witnessed across a multitude of cancer types.
Over the past 20 years, epigenetic misprogramming has been shown to constitute a core component of the initiation and progression of cancer. The observation that regions of the stem cell genome that are specifically marked and transiently silenced by polycomb-group proteins become methylated and completely silenced during the development of cancer has been a key step in our understanding of the role of epigenetic de regulation [17] [18] [19] . This observation led to the proposal of an 'epigenetic stem cell model' of cancer whereby cells acquiring DNA methylation at polycomb-group target (PCGT) genes become erroneously dedifferentiated and are subsequently rendered prone to somatic mutations. Such targeted DNA methylation can be mediated by a specific non-coding RNA, such as HOX transcript antisense RNA (HOTAIR) [20] [21] [22] , which interacts with polycomb repressive complex 2 (PRC2). HOTAIR links the PRC2 component enhancer of zeste homologue 2 (EZH2), a histone-lysine N-methyltransferase enzyme, to histone H3 in order to catalyse the addition of methyl groups to lysine 27 (H3K27), which eventually leads to methylation of DNA in the corresponding region [23] [24] [25] (FIG. 1) . Smoking-related changes in DNA methylation (which specifically affect PCGT gene sites 26 ) in circulating leukocytes can be retained for several years after smoking cessation [26] [27] [28] , which is far longer than the lifespan of differentiated blood cells and, again, strongly supports the view that environmentally triggered epi genetic alterations are most likely embedded in stem cells.
Ample proof exists that PCGT gene methylation is a prerequisite for the transformation of nonmalignant cells into cancer cells 23, 24, [29] [30] [31] and that PCGT gene methy lation seems to accumulate in stem cells as a function of increasing number of cell divisions, which are strongly associated with cancer risk [32] [33] [34] . The extent to which either epigenetic or genetic alterations contribute to the development of cancer has not been assessed, although only a stem cell (whose status is epi genetically determined) has the capacity to survive substantial levels of oncogene-induced DNA damage 35 (FIG. 2a) .
Research over the past 5 years has demonstrated that the contribution of epigenetics to cancer progression is far more complex than was originally appreciated. The findings of several studies have shown that PCGT gene methylation in cells other than those from which the cancer originates can influence cancer development. For example, HAND2, a gene located downstream of the proges terone signalling pathway, is highly expressed during the luteal phase in the endometrial stroma and influences the attenuation of oestrogen-mediated paracrine proliferation signals from the stroma that target endometrial epithelial cells 36 . HAND2 methylation and silencing in the nonmalignant endometrial stroma leads to functional dominance by oestrogen signalling, resulting in complex atypical hyperplasia of the endometrium 37 (FIG. 2b) ; approximately 50% of patients with this pattern progress to cancer 38 . Observational evidence from studies involving other cancer entities supports the view that epigenetic changes in the morpho logically non malignant stroma contribute to both the initiation and progression of cancer [39] [40] [41] [42] [43] .
Although not yet experimentally proved, speculation exists that epigenetic alterations in non-cell-autonomous contributors (such as immune cells and organs that provide endocrine signals) might have important roles in cancer development. Early evidence indicating that PCGT gene methylation (such as HOX gene family methylation in the nonmalignant endometrium) is strongly associated with the presence of cancer in an anatomically distant organ (such as ovarian cancer 44 ) has provided preliminary proof of the concept that analyses of DNA methylation in easily accessible cells can be used to predict an individual's risk of developing cancer.
Besides PCGT gene methylation, a variety of other examples demonstrate how epigenetic alterations can contribute to the development of cancer. A large number of trait-associated genetic variants have, for example, been shown to affect levels of DNA methylation at different CpG sites, including at the binding sites of a variety of transcription factors (such as NFKB1 and CTCF), which are known to be involved in the development of cancer 7 . The importance of this mechanism is strengthened by the observation that CpG sites with aberrant DNA methylation are substantially enriched with such genetic variants, as revealed using GWAS comparing individuals with, and those without colorectal cancer 45 . The fact that methylated cytosines are substantially more prone to undergoing spontaneous deamination 46 and that mutations at CpG sites are frequently observed in cancer 47, 48 provides another example of how aberrant DNA methylation can contribute to the development of cancer.
Cancer risk factors and the epigenome The epigenome, and specifically DNA methylation, is shaped by both heritable and nonheritable factors, which are both also known to have a substantial effect on the development of cancer (FIG. 1) . Therefore, epigenomic alterations hold great promise as objective surrogate markers of the development of cancer.
Genome-epigenome interactions
The mechanisms by which common inherited sequence variations lead to cancer remain largely unknown but might become manifest through their effects on the epigenome in three possible ways.
Cell-autonomous effects. Allele-specific methylation might be associated with methylation quantitative trait loci (meQTLs), single-nucleotide polymorphisms (SNPs) that are associated with the methylation status of specific sites or even entire regions 7, [49] [50] [51] . To date, numerous meQTLs have been identified using novel tools 52 . Efforts to understand the relationship between specific meQTLs and disease processes are currently still at an early stage, although changes in DNA methylation provide one plausible explanation of the downstream effects of SNPs on disease that could be directly quantified in order to achieve more accurate risk modelling. This suggestion is supported by the finding that regions known to contain previously reported and/or, as-yet unidentified poly morphisms associated with cancer risk contain aberrant DNA methylation 53 . Cell-nonautonomous effects. High-penetrance germline mutations (such as mutations in BRCA1/2) are able to modulate the influence of various endocrine factors [54] [55] [56] [57] [58] [59] (such as higher levels of oestrogen and progesterone production in the ovaries). These mutations might then have specific effects on the epigenomes of cells that are receptive to these signals. In the case of oestrogen, the receptive cells include tubal or breast epithelial cells 60 and these changes are typically tissue-type dependent.
'Genetic environmental filter' effects. The activity of enzymes involved in the metabolism of exogenous substances is largely determined by the presence of specific inherited genetic polymorphisms. Such polymorphisms can determine, in part, the effects of environmental exposures on an individual's epigenetic makeup, as evidenced, for example, by the effects of CYP2A6 genotype on nicotine and cotinine clearance 61 . Similarly, a linear relationship exists between serum levels of cotinine, a major metabolite of nicotine, and DNA methylation 62 .
Transgenerational inheritance
The phenomenon of transmitting information from one generation to the next affecting the traits of offspring without altering the germline sequence of the nucleotides (that is, epigenetically) has been demonstrated repeatedly 63, 64 . For example, access to food 65 and exposure to cigarette smoke 66 early in life have repeatedly been demonstrated to influence the phenotypes of future generations. Substantial evidence exists that DNA methy lation of the pro-opiomelanocortin gene is transmitted via the paternal germ line, leading to an increased risk of developing obesity later in life 67 , and that parental diet can affect both cholesterol and lipid metabolism in the offspring 68 . An established link exists between BMI and cancer risk in humans 69 , and obesity itself also seems to trigger epigenetic alterations 70 .
In utero environment
Many women who were exposed in utero to diethylstilbestrol, a synthetic nonsteroidal form of oestrogen provided to their mothers, have a substantially elevated risk of CIN, breast cancer and clear cell vaginal cancer several decades later 71 . Diethylstilbestrol has been shown to upregulate HOTAIR 72 and lead to hypermethylation of HOXA10 (REF. 73 ), a gene involved in genital-tract development in women, in mice exposed to diethylstilbestrol in utero. Taken together, these findings suggest that the carcinogenic effects of diethylstilbestrol are mediated via epigenetic mechanisms. Foetal exposure to other endocrine-disrupting chemicals, including bisphenol A, has also been demonstrated to have carcinogenic effects to vary ing degrees 74 , which are, at least in part, epigenetically transmitted 75 .
Obesity
Obesity is thought to have a substantial and direct effect on the epigenome 70 . Obesity affects the epigenome of organs such as the endometrium 76 , liver 77 , breast 78 and colon 79 , in which obese individuals also have an increased risk of developing cancer 80 . Obesity is likely to cause chronic low-grade inflammation 81 and has the potential to affect DNA methylation via oxidative damage-induced formation and relocalization of epigenetic silencing complexes to PCGT genes in stem cells 82 . These processes are likely to vary among individuals with obesity, even those with identical BMIs, in accordance with their innate environmental response 70 . Habitual changes that lead to a reduction in obesity (such as caloric restriction) substantially slow the epigenetic clock (owing to a reduction in the accumulation of age-associated epigenetic changes) 83, 84 with a resultant decrease in cancer risk [85] [86] [87] .
Smoking
Exposure to cigarette smoke triggers striking epigenetic alterations. Hypomethylation of genes involved in toxin response and metabolism pathways, such as AHRR, CYP1A1 and CYP1B1 (REFS 26, (88) (89) (90) (91) , has been observed across many different tissues, although most of the evidence comes from examinations of blood and/or buccal tissues. Hypomethylation of these genes is not consistently observed in tumour samples 26 , and these epigenetic changes might not be causally involved in tumour progression. However, smoking-induced hypermethylation of genes bivalently marked in human stem cells (such as PCGT genes) can be observed in buccal epithelial cells 26 . A 'smoking' index constructed based on analysis of these hypermethylated sites is highly effective in discriminating between nonmalignant and malignant tissues 26 .
The microbiome and virome
Infections with certain bacteria or viruses have been identified as strong risk factors for specific human cancers 92 , and alterations in the microbiota also might contribute to carcinogenesis 93 . The effects of individual and/or groups of certain microorganisms can cause changes in their human host that are mediated via genetic alterations, epithelial injury and changes in immune system function and/or inflammation 93 . Alterations in the microbiota have also been shown to affect oestrogen metabolism 94 . The microbiota seems to be able to affect the host epigenome through DNAmethylation-dependent pathways 95 . For example, gut bacteria can provide epigenetically active metabolites that are essential for DNA methylation, such as folate, butyrate and acetate, as well as various enzymes and/or cofactors required for epigenetic processes 94 . 
Chronic inflammation
Some cancers can develop owing to chronic inflammatory insults 96 . The carcinogenic processes associated with inflammatory bowel disease, reflux oesophagitis, pancreatitis or pelvic inflammatory disease converge at the level of the transcription factors nuclear factor-κB (NF-κB) and signal transducer and activator of transcription 3 (STAT3), leading to epigenetic reprogramming of the epithelial cells of the affected organ 60, [97] [98] [99] . Again, the majority of genes affected by inflammation-mediated reprogramming are PCGT genes 100, 101 .
Hormones and DNA methylation
Absolute serum levels of hormones, their dynamics over time (such as throughout the menstrual cycle) and their levels relative to those of other hormones (such as the oestrogen-progesterone balance) can all contribute to cancer risk in hormone-sensitive organs 55, 56, [102] [103] [104] [105] . Steroid hormones are key regulators of genes encoding proteins involved in epigenetic programming (such as activation-induced cytidine deaminase (AID) 106 , DNA methyltransferases (DNMTs), EZH2 and others). Dramatic changes in the systemic hormonal environment -as occur, for example, during menopauselead to substantial epigenetic alterations, which are, in part, cell type-specific 107 . In addition, proxy indicators of endogenous prenatal exposure to testosterone (as indicated by anogenital distance 108 or the ratio of digit length 109 ) are associated with prostate cancer risk, consistent with the view that androgens also have an epigenetic imprint, which, after several decades, leads to the development of a specific phenotype.
Age
Age contributes to the cancer risk of a given tissue and/or organ in two possible ways: a cell-intrinsic, tissue-dependent effect whereby cancer risk increases with the number of stem cell divisions; and a cell-extrinsic effect that increases in line with cumulative exposure to environmental risk factors (such as smoking, obesitymediated inflammation and/or viral infections) 3, [110] [111] [112] . Both components lead to an increased risk of cancer with increased chronological age and are intricately linked; this cumulative exposure to cancer risk factors is also thought to accelerate the stem cell division rate of tissues 110 . In addition, DNA methylomes at the two extremes of the human lifespan (those of newborns and those of centenarians) are distinct in the same subset of cells 113 . Like somatic mutations and copy number variations, alterations in DNA methylation gradually accumulate with increased chronological age [114] [115] [116] and with exposure to cancer risk factors independently of age 117 . These factors are thought to reflect cell-intrinsic (such as repeat stem cell divisions) and cell-extrinsic (such as metabolically induced) factors, which both contribute to the accumulation of molecular damage in tissues. Thus, specific changes in DNA methylation in the tissue of origin (or in suitable surrogates) might be informative of cancer risk, as demonstrated in the context of cervical cancer 118 . Supporting this further, an epigenetic mitotic-like clock, 'EpiTOC' 32 , which correlates with the cumulative number of stem cell divisions in the tissue of origin, is universally accelerated in all cancer tissues and pre-neoplastic lesions, again offering promise for cancer risk prediction 32, 118 . By contrast, Horvath's epigenetic clock, a tissue-independent nonmitotic clock that indicates chronological age 119, 32 , seems to be less informative regarding cancer risk 32, 117 .
Current evidence from EWAS Substantial evidence indicates the existence of epi genetic field defects, meaning aberrant epigenetic signatures in nonmalignant tissues located adjacent to the cancer 60, [120] [121] [122] [123] . Within EWAS, a genome-wide set of quantifiable epigenetic marks (such as DNA methy lation) is analyzed in different individuals with the aim of deriving associations between epigenetic variations and a particular identifiable phenotype or trait. Analogous to GWAS 124 , we propose that a minimum of 100,000 CpGs per individual are analyzed in order to apply the term 'epigenome-wide' . When compared with GWAS, several additional challenges to the routine use of EWAS exist. Notwithstanding the correct choice of easy-to-access surrogate tissue, the easily modifiable nature of epigenetic markers creates difficulties in discriminating between cause and consequence and must, therefore, be taken into account when considering the timing of sample collection in relation to the manifestation of the disease. Unlike GWAS, in which variants at singlenucleotide positions are associated with a specific trait, the basis of EWAS is to quantify methylation at CpGs across the genome in a given sample and rank these sites according to their different levels of methylation between patients and controls. To date, both EWAS and studies designed to look at predefined sets of CpGs have been performed. Two principal categories of epigenetic risk predictors exist.
Markers of 'extrinsic risk exposure'
Markers of extrinsic risk exposure are patterns of DNA methylation that reflect exposure to specific exo genous carcinogens. The magnitude of the effect on DNA methylation reflects the individual response and acts as a surrogate marker for the development of cancer in an individual. For example, a dose-dependent relationship exists between the extent of CpG methylation in the AHRR or F2RL3 genes and smoking pack-years 26, 125 , which is a quantitative measure of active lifetime exposure to tobacco smoke. Demethylation at the AHRR or F2RL3 CpG sites (first versus fourth quartile) is associated with a 16-fold and 11-fold increased risk of lung cancer, respectively, even after adjusting for a variety of factors, including current smoking status and duration 126, 127 . These findings have been validated in independent studies with different cohorts 128 . Importantly, the combination of the ten strongest smoking-associated CpGs in blood surpassed the performance of the ten strongest lung-cancer-related CpGs in blood with regard to predicting lung cancer mortality 129 . To date, no clear evidence exists that the aberrant methylation of AHRR observed in surrogate tissues (such as blood or buccal cells) of smokers who are (because they smoke) predisposed to the development of lung cancer actually drives cancer development in the tissue at risk (lung epithelial cells); research into the functional role of AHRR methylation in lung epithelial cell models will need to be carried out.
The findings of an EWAS-based investigation published in 2017 demonstrate that a high BMI is associated with substantial alterations in DNA methylation in blood samples and that these associations are mainly a consequence of obesity not the cause of it 70 . Individuals with obesity ranked in the highest quartile for methylation risk score had a tenfold increased risk of developing type 2 diabetes mellitus compared with those ranked in the lowest quartile 70 . The observation that genes involved in oestrogen signalling (such as those in the p53 and/or NF-kB pathways) are enriched among the obesity-associated genes implies that an obesityassociated DNA methylation signature could enable the incidence of obesity-associated cancers to be predicted, irrespective of the actual BMI of the individual at the time of assessment.
The findings of several studies demonstrate that epigenetic age acceleration (defined as the deviation of epigenetic age from the chronological age of the individual) as assessed in peripheral blood is associated with cancer incidence 85 and mortality 85, 130 in general and, specifically, with postmenopausal susceptibility to breast 87 or lung 86 cancer.
Markers of 'intrinsic risk'
Most established DNA methylation-based markers that enable the prediction of cancer risk were discovered in case-control or population-based nested case-control studies and have not, as yet, been linked with extrinsic risk factors. More than a decade ago, anecdotal reports 131, 132 provided initial evidence that DNA methylation of the gene encoding the DNA mismatch repair protein MLH1 in nonmalignant cells is present in individuals with multiple cancers. Early reports indicated that loss of IGF2 imprinting in lymphocytes is predictive of colorectal cancer risk 133 , although studies investigating DNA methylation in peripheral blood samples taken before diagnosis could not confirm these findings 134 .
Data from the first large study investigating associations between DNA methylation and cancer risk (with a sample size of >1,000 patients and controls) provided a direct link between DNA methylation of the oestrogen receptor-interacting gene ZNF217, serum oestrogen receptor-α bioactivity and breast cancer risk 135 . These data and the majority of data referenced in this section (apart from those referenced in TABLE 3) have been generated based on the analysis of surrogate tissue derived from patients with prevalent (pre-existing) cancers. This reliance predominantly on evidence of this type creates several challenges. For example, the first study involving analysis of a large number of CpGs -approximately 25,000 CpGs (the Illumina 27k methylation array) -was conducted using blood samples from patients with ovarian cancer and from women without cancer 136 and concluded that the timing of sample collection for analysis of DNA methylation and adjustment for sample cell type composition is essential for the valid interpretation of results. Another study using the same assay derived a DNA methylation signature from the peripheral blood of BRCA1-mutation carriers that was highly enriched for PCGT gene hypermethylation and -in two independent cohorts -predicted breast cancer incidence and death independently of family history or other known risk factors 137 , indicating that an epigenetic alteration in circulating leukocytes of BRCA-mutation carriers, which was triggered by cell-autonomous and/or cell non-autonomous factors, predicts the risk of sporadic cancers.
To date, only a very limited number of studies have acknowledged the tissue specificity of the DNA methylome. The majority of ovarian cancers are derived from cells arising from the fallopian tube, the latter of which has the same developmental origins as the endometrium. DNA methylation of HOXA9, a gene that is essential for differentiation of the fallopian tube, is substantially increased in the nonmalignant endometrium of patients with ovarian cancer but not in the adjacent myometrium, which forms the nonepithelial component of the uterus Numerous additional studies, all carried out using analysis of either whole blood samples or a subset of blood cells, have provided evidence of different global 139 or gene-specific DNA methylation patterns in samples collected from patients with testicular 139 , ovarian 140, 141 , colorectal 142 , breast 143, 144 , head and neck 145 or renal 146 cancers or melanoma 147, 148 and from individuals without cancer. An increasing number of studies have identified and/or validated DNA methylation-based markers with data from population-based cohorts to predict the development of breast [149] [150] [151] [152] , bladder 153, 154 or hepatocellular cancers 155, 156 .
Cancer prevention Unlike genetic markers, epigenetic markers are modifiable and not only potentially indicate the risk of developing a certain cancer, or other disease, but importantly can also be used to monitor an individual's response to preventive measures. A study involving 1,092 female volunteers with no apparent signs of cancer showed a reduced rate of methylation of CpGs related to colo rectal cancer in individuals exposed to cancer-preventive agents such as acetylsalicylic acid or hormone-replacement therapy and an increased rate of CpG methylation in smokers and in women with a high BMI 157 . The observation that time since cessation of smoking is reflected in the epigenome of easily accessible organs that are not primarily at risk of smoking-induced cancers 26, 158, 159 indicates that monitoring the effectiveness of preventive strategies could be feasible, even in inaccessible organs, by monitoring changes in DNA methylation in easy to access samples. Besides smoking, changes in DNA methylation associated with obesity have also been shown to be similar in adipose cells and in circulating leukocytes 70 , thus providing further support for this principle. Ongoing research will determine the easy-to-access surrogate tissue that best reflects the epigenetic state of these organs at risk, for which epigenetic field defects are likely to be drivers of carcinogenesis 60, 120 -this is a long-term requirement for the routine implementation of effective monitoring of cancer-preventive measures.
Tissue specificity of the epigenome The specific tissue from which the cancer arises would be the ideal target for the retrieval of cells in order to identify an epigenetic risk signature, although, apart from a few exceptions (such as cervical smears in those with cervical cancer), directly accessing the tissue at risk is not typically feasible, as this often requires the use of invasive procedures (such as bronchial lavage or invasive biopsy sampling of the breast, liver, pancreas, prostate, colon or fallopian tube). We therefore propose that analyses of surrogate tissue samples -from nonmalignant blood cells, buccal and cervical cells and possibly cells from urineshould be used for this purpose. To date, the vast majority of analyses have been undertaken in peripheral blood leukocytes, as these samples can be readily obtained from various cohorts of patients (TABLE 3) .
The fact that the tissues used in EWAS are complex mixtures of many underlying cell types, whereas DNA methylation is cell type-specific 160, 161 , poses a considerable challenge to the analysis and interpretation of EWAS data 162 that is not encountered in analysis of GWAS data. For example, many cancer EWAS conducted using peripheral blood leukocyte samples have demonstrated that most changes in DNA methylation between patients with cancer and individuals without can be attributed to shifts in the proportions of granulocytes, monocytes and lymphocytes, thus reflecting a specific and substantial immune response to the presence of cancer 145, 154, 163 . In women with primary ovarian cancer or residual disease after chemotherapy, such shifts in DNA methylation provide highly accurate predictions of disease status (AUC >0.8). However, when used to assess patients with ovarian cancer who had received chemotherapy and who did not have evidence of residual disease (with ovarian cancer serum marker cancer antigen 125 (CA125) levels <35 U/ml), DNA methylation profiles were largely indistinguishable from those of age-matched women without ovarian cancer. Changes in DNA methylation associated with such shifts in cell type composition could be useful for general diagnostic purposes, although they do not generally represent epigenetic alterations that potentially drive carcinogenesis. Identifying the latter requires the inference of differentially methylated CpGs (DMCs) with methylation patterns that are not driven by underlying changes in cell type composition. To help address this challenge, efforts such as the International Human Epigenome Consortium 164 and BLUEPRINT network 165 are underway and are designed to generate reference DNA methylation profiles for all major human cell types. These reference DNA methylation profiles, although derived from specific individuals (and thus potentially confounded by factors such as genotype and age), can be used in the deconvolution of bulk-tissue DNA methylation profiles 166 , thus providing reasonably accurate estimates of the underlying proportions of cell types in independent samples, as confirmed using matched flow cytometry and/or magnetic-activated cell sorting-based cell count data 167 (FIG. 3) . These cell type fraction estimates can subsequently be used to adjust the DNA methy lation data, thus enabling the identification of DMCs that are not driven by changes in cell type composition 166, 167 . Using this approach, a meta-analysis of data from EWAS involving blood samples from patients with solid tumours further confirmed that very few similarities in DMCs between cancers and controls remain after adjustment for cell type composition 153 . These residual DMCs were found to map to cancer-related pathways 153 , although their interpretation and relevance to the corresponding cancer type is still unclear. Further progress will likely require the identification of changes in DNA methylation in either the cell of origin of the cancer or in surrogate tissues and/or cells that more closely represent the cell of origin of epithelial cancers. Ongoing work will demonstrate whether or not analyses involving a combination of the epigenomes of several surrogate tissues such as blood (also capturing the contribution from the stroma and/or immune system) or cervical and buccal cells (capturing the contributions of hormonedependent and independent risk factors, respectively) might provide the best level of accuracy.
Cell-free DNA in serum or plasma currently can be used to monitor the effectiveness of cancer treatments and to identify the presence of treatment-resistant clones. In this context, somatic genetic or epigenetic alterations, which have accumulated in the established cancer and have been released into the liquid phase (liquid biopsies), can be analyzed. This approach, by definition, is not currently considered useful for risk-prediction purposes, as discussed in the context of this Review. However, having said this, some preliminary evidence now exists that organ-specific DNA methylation patterns can be detected in individuals without cancer 168, 169 . Whether analyses of cell-free DNA in plasma and/or serum can be used to assess the future cancer risks in specific organs needs to be determined once sufficiently large populationbased cell-free DNA repositories (that are not massively contaminated with DNA released from blood cells) have become available and their original donors monitored for a sufficient amount of time to identify those individuals who eventually developed cancer.
In summary, tissue specificity is a hallmark of the epigenome. The vast majority of EWAS studies have analyzed the epigenomes of peripheral blood cells. To date, not one study has analyzed the epigenetic features of several surrogate tissues (such as blood and buccal cells) from the same individuals at the same time in order to identify the optimal surrogate tissue to predict an individual's future risk of a specific cancer entity. Thus far, whether epigenetic profiles in blood cells (the vast majority of EWAS analyzed the epigenomes of these cells) are either a surrogate of the epigenome in the tissue at risk or purely an indication of the epi genetic status of immune cells, and thereby reflective of their anti-neoplastic capacity, or a combination of both of these possibilities remains to be determined. The limited data available correlating the epigenomes of circulating immune cells with those of various regions of the brain from the same individuals reveal the presence of rather weak correlations only, indicating that the blood epigenome provides a very approximate reflection of the epigenome of the brain 170 .
Translational challenges Choice of analysis method
The choice of analysis method will depend on the size and costs of the study, the heterogeneity of the samples and whether quantitative assessments of single CpG methylation or patterns of DNA methylation in a specific region are required
.
Choice of surrogate tissue
The findings of studies published in the past few years have indicated that cancer risk prediction might be possible using DNA methylation profiles obtained from blood samples 86, 171 , although levels of predictive accuracy are low, have an unclear mechanistic basis and would require further validation before routine use. In the context of cancers observed only in women, cervical smears, which obtain samples from hormone-sensitive tissues, are the most promising alternative. Cervical smears might serve to identify relevant epigenetic biomarkers of cancer risk, not only for cervical cancers but also for endometrial and ovarian (owing to their common embryological origins) as well as breast (hormonally induced) cancers in prospective case-control settings nested within larger prospective clinical trials. Buccal cells (epithelial cells directly exposed to smokebased and possibly other environmental toxins) might be the best surrogate tissue for predicting lung cancer risk and urine samples (containing epithelial cells from the urethra, which shares an embryological origin with the prostate) might be best suited for predicting prostate cancer risk.
Analytical challenges
The identification of alterations in DNA methylation that might indicate cancer risk is particularly challenging because the most relevant comparison is between nonmalignant cells that are at a high risk of undergoing malignant transformation and those that are not. Comparisons of data from these two apparently similar sets of cells is statistically challenging 118 owing to technical confounders, biological confounders (such as cell type heterogeneity) and the likely stochastic nature of changes in DNA methylation that precede carcinogenesis.
Technical confounders (such as batch effects) are frequently observed in omics datasets 172 , although many statistical algorithms are available that can successfully be used to adjust data for the effects of these Nature Reviews | Clinical Oncology confounders [173] [174] [175] . Cervical smears, comprising various types of epithelial and immune cells, often contain substantial levels of variation in immune cell fractions among unrelated women, making adjustments for these variations vital. Statistical methods, specifically designed to compensate for variations in cell type composition, have also been developed 166, 176 and enable the identification of DMCs that are not driven by changes in tissue composition (FIG. 3) .
Proportion of cells
In the context of cancer risk prediction, an additional statistical challenge arises because differences between nonmalignant cells with a low risk of malignant transformation and those with a high risk of neoplastic transformation are expected to be infrequent and stochastic. The nature of these differences means that standard algorithms based on the selection of DMCs might fail to determine differences between these two groups 118 . Cancer cells often contain widespread changes in DNA methylation that are identifiable using DMC-based approaches and account for most of the variation in the data 17, 120 , while precursor cancer cells generally exhibit a much more hetero geneous and stochastic pattern of DNA methylation 118, 120 . These differences are possibly caused by nonmalignant cells not undergoing neoplastic transformation and consequently not being selected for. A proof-of-principle study with results published in 2012 confirmed this suggestion in the context of cervical cancer 118 . The findings of this study demonstrated that the DNA methylation patterns of cells collected in cervical smears from women who developed a CIN2+ lesion 3 years after sample collection could be distinguished from those of women who remained cancer-free only if a statistical feature selection paradigm that enabled the selection of CpGs with heterogeneous and stochastic patterns was adopted, and this filtering enabled the detection of so-called differentially variable CpGs (DVCs). Such DVCs manifest as outlier DNA methylation events that are seen in only a very small fraction of the women who later develop CIN2+ lesions. DVCs seem to be stochastically distributed across different individuals, although the pattern of distribution is distinctively nonrandom across the genome of any one individual, highlighting the existence of specific regions of the genome that are more susceptible than others to interindividual variations in DNA methylation, as previously observed 118, [177] [178] [179] . Thus, as shown in the context of cervical carcinogenesis 118 , risk prediction by measuring the accumulation of deviations in DNA methylation from the nonmalignant state across a well-defined set of DVC loci, an approach called EVORA (epigenetic variable outliers for risk-prediction analysis), might be possible 118, 138 . The EVORA framework currently awaits further validation, although independent strong Box 1 | Potential methods of assessing the DNA methylome for risk-prediction purposes
The majority of technologies used to quantify DNA methylation rely on the principle of sodium bisulfite-induced deamination of unmethylated cytosines to uracil, followed by either microarrays or sequencing as a readout. Clinical assays require a targeted approach, enabling the screening of large sample sets by covering only selected regions of interest. This approach enables a reduction in both workload and overall costs.
For discovery (feature selection)
• Whole-genome bisulfite sequencing (WGBS). A labour-intensive method involving DNA fragmentation, ligation of adapters, purification of ligation products, bisulfite modification, PCR and sequencing. Theoretically, WGBS is able to capture all CpGs in the genome at a single-nucleotide level of resolution.
• Reduced-representation bisulfite sequencing (RRBS). A sequencing method that enriches for CpG-rich regions of the genome by digesting genomic DNA using the type 2 restriction enzyme HpaII. RRBS covers 85% of CpG islands and 60% of promoters. Steps involve DNA digestion, end-repair, A-tailing, adapter ligation, fragment-size selection, bisulfite modification and sequencing.
• Methylation arrays. Arrays targeted to the methylated regions (CpG islands) of the genome. For example, the Methylation EPIC BeadChip (Illumina5), covers 99% of RefSeq genes and 95% of CpG islands and enables the interrogation of >850,000 methylation sites. Methylation arrays also rely on bisulfite modification but are generally less labour-intensive than sequencing-based approaches.
• Affinity enrichment methods. Methods based on affinity purification of methylated DNA regions using either an antibody directed against 5-methylcytosine (methyl-DNA immunoprecipitation) or against methyl-binding proteins (methyl-CpG binding domain protein capture). The methylation status of isolated DNA can then be assessed using PCR, microarrays or sequencing approaches.
For clinical assays
• Custom arrays. Specific regions of the genome can be investigated using custom-designed arrays. Various companies offer customized array services for the creation of targeted assays.
• Targeted bisulfite sequencing. Use of specifically designed primers and next-generation sequencing technology for the analysis of targeted genomic regions of interest. The cost per sample is reduced, but the single-nucleotide resolution is maintained.
• Pyrosequencing. DNA sequencing based on the 'sequencing by synthesis' principle. This approach relies on the detection of pyrophosphate release upon nucleotide incorporation. A light signal is then generated that enables the quantitative analysis of methylation.
• Quantitative PCR involves the amplification of bisulfite-modified DNA with fluorescent primers that hybridize with predefined methylated regions, such as those seen in MethyLight or digital PCR.
evidence of the validity of this approach has been obtained in women with breast cancer by comparing nonmalignant breast tissue samples from women without breast cancer with the apparently nonmalignant breast tissue located adjacent to the tumours of women with breast cancer 120 . EVORA was able to distinguish between nonmalignant breast tissue from patients with breast cancer and that of women without breast cancer with an AUC of 0.84.
Sample size
The search for epigenomic risk markers is often hampered by the analysis of relatively small sample sizes (compared with those used to search for genomic markers) owing to the high costs of epigenomic analyses. Consequently, spurious associations between CpGs and cancer risk might have previously been found, and the extent of true associations might have been exaggerated. Therefore, the ideal scenario of obtaining comprehensive data from a single large-scale, prospective cohort study might not be reached owing to the absence of large population-based sample collections. The evidence base for specific associations might be increased by also considering results obtained using other prospective study designs that include only incident cases and that are matched to well-defined population-based controls (TABLE 3) . Such studies enable unbiased estimations of relative risks. The application of simulations for EWAS 180 and calculations based on our data 26, 118, 120, 121, 137 suggest that 300 affected individuals and 300 nonaffected individuals are sufficient to enable the discovery of DMCs. Validation studies involving data from independent, population-based cohorts are then required to confirm any associations and to validate the absolute risks that apply to the general population.
Data storage and sharing
Adopted by the European Union in 2016 and coming into effect in 2018, the General Data Protection Regulation (GDPR) 181 provides legal guidance on the management of privacy risks associated with specific data types (such as personal data, genetic data, data concerning health, biometric data or other sensitive data), levels of identifi ability (anonymous, pseudonymized or identifiable data) and data uses (such as clinical care and/or research). Data that are entirely anonymous fall outside of the purview of the GDPR, and the sharing of pseudonymized (coded) and identifiable data are strictly regulated. Future challenges lie not only in the possibly narrow or broad interpretation of the GDPR and its implications for research and clinical data in Europe but also in the currently unknown repercussions for intended data sharing beyond the borders of Europe, especially in the USA, which has a more progressive approach to research data privacy. A code of conduct for health-related data is being developed to both mitigate possible untoward restrictions and to facilitate data sharing both within Europe (BBMRI-ERIC) and beyond Europe (GA4GH).
In the context of the epigenetic risk-prediction test, the main challenge for the scientific community would seem to be characterizing the identifiability of epigenomic information. The above regulations raise several questions as to whether epigenomic information enables the identification of an individual, either directly or indirectly, and whether or not such data should be considered 'personal' , 'sensitive' , 'genetic' or 'health-related' information. The notion of identifiability is itself elastic over time but has been circumscribed by a 'reasonable likelihood' test of re-identifiability. Such questions are important to consider when addressing the specific issues raised by the need to share epigenomic information.
Challenges to implementation
Combining information on genetic variants with data on environmental and lifestyle-related risk factors would provide an improved level of risk stratification. The use of epigenetic changes captures the interactions between observed and unobserved risk factors at the cellular level in each individual 182 , although the assessment of these risk factors via questionnaires and retrospective selfreporting is of limited reliability and is susceptible to, for example, recall bias 183 . The implementation of both risk-tailored approaches to cancer prevention and programmes designed to enable an accurate diagnosis of cancer early in the course of disease is a multistep process and raises a number of challenges for both policymakers and the public they serve (FIG. 4) . The organizational challenges to be addressed include providing equitable access to risk assessment and risk-tailored interventions, preparing and training the workforce, building an infrastructure for assessing the quality of tests and services and the development of IT platforms and data storage capacity. Using epi genomebased risk assessments poses additional organizational challenges owing to the plasticity of the epigenome, thus indicating a need for ongoing risk assessments over time and varying recommended levels of intervention according to levels of risk. On the basis of the available data on smoking and methylation status (changes in DNA methylation as a function of accumulating pack-years and of time after cessation of smoking 26, 158 ), we speculate that an epigenetic risk-prediction test would likely have to be repeated every 3-5 years in order to recalculate an individual's risk.
Ethical issues
The epigenome acts as a surrogate readout for the combined effects of heritable and lifestyle-related factors and raises several issues. These issues include the extent to which responsibility for a healthy lifestyle can be attributed to the individual and to what extent should individuals be held accountable for their health. Other examples include how clinicians can ensure that individuals are making a voluntary and well-considered informed choice for or against undergoing a test that might reveal complex information regarding the risks of several different malignant or nonmalignant diseases with varying ages of onset. For example, signatures for cervical or breast cancer might reflect the individual response to smoking and obesity and, as such, also could indicate the risks of lung cancer [126] [127] [128] 158 and type 2 diabetes mellitus 70 , respectively. This possibility requires the development of new informed consent paradigms (including broad tiered and staged models) 184 , shared decision-making approaches and novel patient-decision-making tools in both a clinical and population screening context 185 . Furthermore, implementation of epigenome-based risk predictions in the latter context could require a reinterpretation of current ethics frameworks regarding the use of population screening.
Legal issues
The development of genomics and other omics sciences, including epigenomics, has eroded the once clear boundary that existed between research and clinical care. This new translational space is conducive to improving health-care outcomes but also raises legal issues owing to the reversibility of epigenetic risk factors and the dynamic, sometimes transgenerational, nature of epigenetic data. Relevant legal issues include the consolidation of a cost-effective pathway for regulatory approval of new epigenetic tests, clarification of the limits of liability of researchers and clinicians (such as when returning research results or incidental findings, including epigenetic test results, to a patient's medical file and when updating patients on important changes in the interpretation of epigenetic material), clarification of the privacy and confidentiality rights of the patient versus those of biologically related family members (siblings, children and others) and the promotion of equal access while also encouraging the level of data sharing necessary for the advancement of epigenetic science 186 
Risk communication
Risk assessments conducted on an individual basis require informed consent and the provision and communication of evidence-based information in a manner that is appropriate to the patient's level of education and engagement.
Some of the challenges associated with communicating the findings of epigenome-based risk assessments are identical to those associated with existing genetic tests. Individuals need to be informed upfront (such as by using fact boxes 187 ) of their age-adjusted baseline risks, the benefit to harm ratio of undergoing or not undergoing the test and the modified benefit to harm ratios associated with current approaches to cancer screening and prevention as a consequence of the test 188 . The communication of epigenetic screening results, however, has additional layers of complexity. Individuals need to be informed about the complex cancer-specific interplay between genetics, the environment and their behaviour and, additionally, that testing for epigenetic factors will reveal some of their past environmental exposures (such as smoking, alcohol consumption and others). The health-care workforce must, therefore, be trained in the interpretation [189] [190] [191] [192] and communication of the results of risk-prediction tests.
Evaluating benefits and harms
Scientific evidence needs to demonstrate additional levels of benefit of any new risk-tailored screening or prevention strategy, with an acceptable benefitharm and cost-effectiveness ratio when compared with the current standard of care [193] [194] [195] . Decision analytical modelling is a useful quantitative approach to synthesizing the best available level of scientific evidence, including data on epidemiological parameters, test performance, prognosis, treatment effectiveness, quality of life and economic aspects. Evaluations of the trade-off between benefits, harms and costs of alternative interventional strategies are useful [196] [197] [198] . Decision models are designed to simulate the development of the disease and the consequences of different screening and/or prevention strategies, including specific medical pathways 197, 199 
Adaptation of existing infrastructure
The leveraging of screening programmes that already exist provides a key opportunity for the rapid real-life evaluation and roll-out of new tests. In most highresource settings, the infrastructure required for cancer screening programmes is already available and can be used to explore new frontiers in the use of omics technologies for cancer prevention. Such programmes have the inherent potential to enable the testing of novel biomarkers through so-called randomized health services studies (RHS) 200 . Once evaluated using an RHS design, new screening tests -if found to be superior to the previous approach -could be immediately implemented because the programme has already been included in the testing phase.
Future directions
Epigenetic-based risk-prediction models provide state-of-the-art opportunities for the delivery of personalized medicine and interventions tailored to each individual's level of risk in order to improve human health by reducing the risk of cancer. Several considerable challenges have been identified, and further research is required, although the implementation of such risk models is potentially feasible and, when available, would likely satisfy most of the criteria required for effective risk prediction. Such challenges include the encapsulation of both genetic and nongenetic risk-referring factors using a single omics platform that is biologically stable and technically reproducible and that enables a predictive score to be derived using easily accessible tissues that are relevant to cancer development or are able to capture risk-referring signals. This platform should, ideally, also be suitable for monitoring the effectiveness of risk-reducing measures.
Conclusions
Epigenomics-based approaches to individualized cancer prevention and screening and/or early detection programmes are promising but will require international collaboration among multidisciplinary teams with expertise in omics, bioinformatics, epidemiology, public health, economics, decision analysis, ethics, law, risk communication and engagement of the scientific community with health-care professionals, policymakers and the public. In order to develop epigenomics-based approaches to cancer prevention, multidisciplinary research involving international consortia is needed to overcome the various scientific challenges. The implementation of DNA methylation-based methods predicting the development of specific cancers requires the evaluation of long-term consequences regarding the likely benefits, harms and levels of resource utilization. Depending on the implementation (such as screening or follow-up testing), several different factors might all have important implications for the trade-offs between benefits, harms and costs. The accuracy of a test determines both the number of true positive and false positive test results triggering further follow-up investigations and, therefore, has an effect on both the benefits and risks of possible unnecessary treatments. The screening interval should be sufficiently long to balance the likelihood of benefits and harms but sufficiently short to achieve the optimal level of added benefit from early detection and treatment. Adherence to screening, the effectiveness of treatments and the potential risks of adverse effects might all influence the overall effectiveness and cost-effectiveness of the implementation of DNA methylation-based intervention strategies. Decision analysis models can help to evaluate the effects of specific factors and their interactions on effectiveness and cost-effectiveness and to inform clinical guideline algorithms, thus optimizing outcomes. NPV, negative predictive value; PPV, positive predictive value.
